Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis

Marieke Begemann1*, Mikela Leon1, Harm Jan van der Horn2, Joukje van der Naalt2 & Iris Sommer1

Outcome after traumatic brain injury (TBI) varies largely and degree of immune activation is an important determinant factor. This meta-analysis evaluates the efficacy of drugs with anti-inflammatory properties in improving neurological and functional outcome. The systematic search following PRISMA guidelines resulted in 15 randomized placebo-controlled trials (3734 patients), evaluating progesterone, erythropoietin and cyclosporine. The meta-analysis (15 studies) showed that TBI patients receiving a drug with anti-inflammatory effects had a higher chance of a favorable outcome compared to those receiving placebo (RR = 1.15; 95% CI 1.01–1.32, p = 0.041). However, publication bias was indicated together with heterogeneity (I² = 76.59%). Stratified analysis showed that positive effects were mainly observed in patients receiving this treatment within 8 h after injury. Subanalyses by drug type showed efficacy for progesterone (8 studies, RR 1.22; 95% CI 1.01–1.47, p = 0.040), again heterogeneity was high (I² = 62.92%) and publication bias could not be ruled out. The positive effect of progesterone covaried with younger age and was mainly observed when administered intramuscularly and not intravenously. Erythropoietin (4 studies, RR 1.20; p = 0.110; I² = 76.59%) and cyclosporine (3 studies, RR 0.75; p = 0.189, I² = 0%) did not show favorable significant effects. While negative findings for erythropoietin may reflect insufficient power, cyclosporine did not show better outcome at all. Current results do not allow firm conclusions on the efficacy of drugs with anti-inflammatory properties in TBI patients. Included trials showed heterogeneity in methodological and sample parameters. At present, only progesterone showed positive results and early administration via intramuscular administration may be most effective, especially in young people. The anti-inflammatory component of progesterone is relatively weak and other mechanisms than mitigating overall immune response may be more important.

Traumatic brain injury (TBI) remains one of the biggest public health problems and represents a major cause of death or severe disability in young people and adults1,2,3. Benedictus et al.3 reported that a significant proportion of patients continues to encounter physical (40%), cognitive (62%), behavioral (55%) and social (49%) problems that may prevent them to return to their former social activity and work after TBI, where severity of injury is associated with higher frequencies3. Even patients with good recovery (58%) report problems in one or more of these domains. With a growing awareness of the deleterious effects of TBI, early interventions to ameliorate the effects and improve outcomes are at the heart of science4.

In the central nervous system (CNS), an inflammatory response occurs directly after TBI, involving both resident and peripheral immune cells as measured both in blood and in the brain5,6. The effects of this accompanying inflammatory reaction are considered to have both beneficial and harmful aspects. Immune activation is needed for neuro-reparative mechanisms after brain injury, defends against invading pathogens and repairing damaged brain tissue. However, ongoing neuro-inflammatory responses also contribute to the development of

---

1Department of Biomedical Sciences of Cells and Systems, Section Cognitive Neurosciences, University Medical Center Groningen, University of Groningen, Anton Deusinglaan 2, 9713 AW Groningen, The Netherlands. 2Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3email: m.j.h.begemann@umcg.nl
The observed association between TBI and neuroinflammation has stimulated research on the application of immune modulating components as a potential treatment option. Animal studies testing the efficacy of agents with anti-inflammatory actions have provided promising leads for clinical trials. For example, administration of erythropoietin, which has mild anti-inflammatory properties but also many other actions, significantly reduced edema and improved cognitive function in a mouse experimental TBI model. With the same drug, reduction of hippocampal neuron loss and enhanced neurogenesis in the injured cortex and hippocampus has been observed, which led to improved sensorimotor function and spatial learning in mice. Other components with anti-inflammatory properties have shown similar beneficial effects, yet results vary according to the investigated injury model and/or treatment window. Moreover, translating positive findings from animal studies to clinical results has proven difficult, with some studies finding positive results for immune mediating interventions in patients, while other results are negative.

A structured overview of the effects of drugs with anti-inflammatory properties after TBI may help to determine possible future clinical studies and eventually improve care for TBI patients. Current study aims to provide a quantitative summary of randomized controlled studies in patients with TBI providing drugs with anti-inflammatory aspects. Many pharmacological agents have at least some degree of anti-inflammatory action, either as primary function, or as for others it is only one of their mechanisms of action. In order to be as inclusive as possible, we selected all agents that have some anti-inflammatory aspects, as demonstrated in (rodent) experimental settings. This results in a very broad range of agents, which have one important feature in common: their anti-inflammatory effects.

Method

Search strategy. A systematic literature search was performed using PubMed, Cochrane Library and the National Institutes of Health Website ClinicalTrials.gov, following PRISMA guidelines. To identify other potentially eligible studies, we searched through citations and references from all relevant publications for cross-references. Search cut-off date was August 2019. There were no year or language restrictions. Following a previous study investigating the effects of anti-inflammatory agents in schizophrenia treatment, the search strategy consisted of the combination of the following keywords: traumatic brain injury OR head injury OR head trauma AND the specific pharmacological components: NSAIDs (non-steroidal anti-inflammatory drugs, i.e. aspirin, celecoxib, ibuprofen, diclofenac, naproxen), devunetide, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) fatty acids, estrogen, minocycline, NAC (N-acetyl-L-cysteine) and corticosteroids (i.e. prednisone, prednisolone, hydrocortisone, methylprednisolone, dexamethasone, cortisol, triamcinolone, betamethasone), transplantation adjuncts (tacrolimus, cyclosporine, everolimus, serolimus, mycophenolate mofetil), cytostatics (bexarotene, methotrexate, cyclophosphamide), melatonin, progesterone, and erythropoietin. Progesterone and erythropoietin were added as search terms after a manual search of citations from retrieved studies, as anti-inflammatory mechanisms have been reported for both components.

Inclusion criteria. Studies and trials meeting the following criteria were included.

1. Study design: randomized, single or double-blinded, placebo-controlled trials.
2. Condition: patients with a clinical diagnosis of TBI or diffuse axonal injury (DAI) regardless of its severity (mild, moderate, severe).
3. Intervention: pharmacological components with confirmed anti-inflammatory mechanisms and effects. Agents could be administered in any dose, by any route, for any duration of time initiated within 24 h after TBI.
4. Study outcome: neurologic and functional outcome measured by the Glasgow Outcome Scale (GOS) or Glasgow Outcome Scale-Extended (GOS-E).
5. Studies reported sufficient information to compute common effect sizes (ES) statistics, or authors were able to provide data upon request.

Outcome measures. The main outcome was functional outcome as measured using the Glasgow Outcome Scale (GOS) or Extended Glasgow Outcome Scale (GOS-E), which scores are dichotomized to favorable or unfavorable outcome. The GOS rates patient status into one of the five ordinal outcome categories: dead, vegetative state, severe disability, moderate disability or good recovery. Because of the ceiling effects, the GOS has been modified into GOS-Extended to address these shortcomings. The GOS-E provides eight categories by splitting severe disability, moderate disability, and good recovery into a lower and upper category. The dichotomization into favorable (good recovery and moderate disability) and unfavorable (severe disability, vegetative state, and death) category has been used extensively in RCTs. Effects are usually estimated by means of the proportion of favorable outcome in each group.

Study selection and data extraction. Titles and abstracts were screened for studies that did fulfill the inclusion criteria. Studies that appeared relevant after screening were selected for further full-text review. The following variables were extracted from each study: author, year of publication, study design, condition, and drug intervention, patients’ characteristics, for treated and control group separately: number of patients enrolled and percentage of males in each group, age [as mean (M) and standard deviation (SD) or median (Me)
and interquartile range (IR)]. In case N of patients enrolled for the treatment and control group was unclear, we used N of patients included in the final analysis. Additionally, Glasgow Coma Scale scores at initial assessment and treatment protocols (dosage, the way of application, and treatment duration) were extracted.

Studies differed in terms of the number of follow-up measurements. In line with previous literature, we preferably used the outcome reported at 6 months after the intervention or end of the follow-up period22. Furthermore, Wright et al.21 reported outcomes separately for a moderate and a severe TBI group. As the moderate group was small in sample sizes, outcomes were combined in our analyses. The same was done for Robertson et al.22, who compared two different dosage regimens of erythropoietin (Epo) to one placebo group.

**Statistical analysis.** Effect sizes were computed using Comprehensive Meta-Analysis Version 2.0, Biostat23. Analysis was run on all studies eligible for quantitative analysis. Dichotomous outcomes comparing recovery rates between treatment and control groups were analyzed as the risk ratio (RR), testing the null hypothesis that there are no differences (true RR is 1.0), while a RR greater than 1 indicates that patients in the intervention group were more likely to improve than those treated with placebo.

All included studies were combined to calculate a mean weighted ES for the effect on functional outcome, using a random effects model. Individual components were also separately evaluated. To investigate whether studies could be combined to share a common population effect size, the Q-value and I^2-statistic were evaluated for each analysis. The Q-statistic tests the existence of heterogeneity and displays a chi-square distribution with k − 1 degrees of freedom (k = number of study samples). Q-values higher than the degrees of freedom (df) indicate significant between-studies variability. I^2 indicates the proportion of the observed variance in true effect sizes rather than sampling error, ranging from 0 to 100%. Heterogeneity can be interpreted as low (≤ 25%), moderate (25–50%) or high (> 50%). Further investigating potential heterogeneity between studies, moderator analyses were performed to evaluate whether study characteristics covaried with intervention effectiveness; including time to treatment after injury (hours), intervention duration (hours) and age (years) and gender distribution (% male) of the included study samples. Additionally, subgroup analyses were performed to evaluate whether the effect on favorable outcome differed between the pharmacological agents. When relevant and in case of sufficient study samples, moderator analyses were repeated per subgroup, in addition to stratifying subgroup analyses by administration route of the individual drug components to examine potential differences in the effect on favorable outcome. p values < 0.05 were considered significant.

When interpreting meta-analytic outcomes, the possibility of an upward bias of the calculated effect sizes due to the omission of unpublished, nonsignificant studies must be taken into account. Potential publication bias was investigated by means of a visual inspection of the funnel plot and Egger’s test15 was evaluated when appropriate (i.e., analysis included a range of study sizes, with at least one of ‘medium’ size (p < 0.05 two-tailed). Moreover, the fail-safe number of studies (NR) was calculated, providing an estimate of how many unpublished null findings would be needed to reduce an observed overall significant result to non-significance (the fail-safe number should be 5k + 10 or higher [k = number of studies in a meta-analysis] to rule out a file drawer problem.

**Results**

**Search results.** The search strategy yielded 1791 results (see Fig. 1). After screening and full-text reading, studies meeting defined criteria were included for qualitative synthesis. In total 15 studies (cyclosporine: three studies; erythropoietin four studies; progesterone eight studies), including 3734 patients were finally eligible for quantitative analysis. Corticosteroids have been previously evaluated in a Cochrane review24 (updated in 2009), including the large CRASH study that dominated the results24–26. Moreover, as we did not identify any new corticosteroid studies, it was decided not to pool these results in current meta-analysis. The characteristics of the fifteen trials included in this meta-analysis are presented in Table 1 (see Appendix Table E1 for the number of patients with favorable outcome within each individual study, separately for treatment and control group).

**Overall meta-analysis.** The overall analysis, including 15 studies, showed that the mean risk ratio was 1.15 (95% CI 1.01–1.32, p = 0.041), indicating that drugs with anti-inflammatory properties as received in the intervention group increased the chance of a favorable outcome relative to placebo. As shown in Fig. 2, three studies showed a significant individual RR (p < 0.05) favoring the treatment group32,34,37.

The Q-value of 39.24 (p < 0.001) indicated that the variability among studies was higher than would be expected due to sampling error alone and that there is evidence of variance in true effects. Heterogeneity was high (I^2 = 64.32%), indicating that over 64% of the dispersion reflects the differences in true effect sizes, while the remaining 36% can be attributed to random sampling error. Moreover, publication bias was indicated by the significant Egger’s test (t = 2.23, p = 0.043) and when observing the funnel plot, the trim-and-fill procedure suggested four studies were potentially missing, reducing the RR to 1.02 (95% CI 0.96–1.09, see Fig. 3). The number of unpublished negative studies needed to render our significant RR of 1.15 nonsignificant was NR = 26.

When further investigating heterogeneity, moderator analyses showed that the treatment effect of drugs with anti-inflammatory properties on favorable outcome was not associated with intervention duration, age or gender distribution (% male). Time to treatment after injury was evaluated using a categorical approach, as 10 out of 15 studies reported a similar administration time (8 h after injury). The effect of drugs with anti-inflammatory properties on favorable outcome did not differ between the 11 trials with a faster administration time (within 8 h of injury) and the four trials with a longer administration time (Q(1) = 0.665, p = 0.415). However, while the combined RR of 1.05 for studies with a longer administration time did not reach significance [subtotal n = 876; 95% CI 0.80–1.38, p = 0.153; Q(3) = 4.73, p = 0.193; I^2 = 36.60%], the trials with a faster administration resulted in a combined RR of 1.20 favoring the effect of drugs with anti-inflammatory properties (subtotal n = 2858; 95% CI 1.02–1.42, p = 0.033) but with significant heterogeneity (Q(10) = 34.49, p < 0.001; I^2 = 71.01%).
Subgroup analyses. The effect on favorable outcome did not differ across the three drugs with anti-inflammatory agents properties ($Q(2) = 4.54, p = 0.103$). However, when evaluating RR according to subgroup, progesterone showed a significant risk ratio of 1.22 (95% CI 1.01–1.47, $p = 0.040$), see Fig. 2. Notably, the Q-statistic was significant and heterogeneity was high ($Q(7) = 18.88, p = 0.009; I^2 = 62.92\%$). Publication bias was indicated by the significant Egger’s test ($t = 4.45, p = 0.004$) and when observing the funnel plot, the trim-and-fill procedure suggested four studies were potentially missing, reducing the RR to 1.10 (95% CI 0.93–1.28). Fail-safe $N_f$ was 12. Moderator analyses indicated that age was significantly related to the effect of progesterone on favorable outcome, with lower RR in study samples with a higher mean age ($Q = 9.92$, slope $-0.07$, $p = 0.002$; see Fig. 4). Gender distribution (%) did not moderate this effect ($Q = 1.64; p = 0.200$). Moderator analyses could not be performed for time to treatment nor treatment duration as included studies showed little variation in those parameters. The positive effect of progesterone did significantly differ in terms of administration route ($Q = 15.73, p \leq 0.001$). Although based on a relatively small number of studies, results were homogeneous and showed that progesterone only showed a beneficial effect on outcome when administered intramuscularly (RR 1.41, 95% CI 1.41–1.17, $p < 0.001; I^2 = 0\%$) but not when patients received progesterone intravenously (RR 0.97, 95% CI 0.97–1.05, $p = 0.420; I^2 = 9.72\%$).
| Study (author, year) | Condition | Study design | No. of patients enrolled (male %) | Mean age (SD or IQR) | GCS included patients | Intervention | Outcome included in meta-analysis |
|---------------------|-----------|--------------|-----------------------------------|---------------------|----------------------|--------------|----------------------------------|
| **Progestrone**     |           |              |                                   |                     |                      |              |                                  |
| Wright22            | TBI       | RCT DB       | 77 (70%)                          | 35.3 (14.3)         | 4 < GCS < 12         | Loading dose 0.71 mg/kg at 14 mL/h first hour, then reduced to 10 mL/h to deliver 0.5 mg/kg per hour for next 11 h. Five 12-h maintenance infusions delivered at 10 mL/h for total of 3 days of treatment | GOS-E 30 days |
| Xiao22              | TBI       | RTC DB       | 82 (70%)                          | 30 (11)             | GCS ≤ 8              | 1 mg/kg via intramuscular injection, once per 12 h for 5 consecutive days | GOS 6 months |
| Aminmansour24       | TBI/DAI   | Simple random sampling | 20 (80%) | 28.0 (7.4) | GCS ≤ 8 | Within 8 h after injury, 1 mg/kg of progesterone intramuscularly every 12 h for 5 days | GOS 6 months |
| Shakeri29           | DAI       | RCT SB       | 38 (100%)                         | 34.0 (12.5)         | GCS ≤ 8              | 1 mg/kg every 12 h for 5 days | GOS 3 months |
| Skolnick30          | TBI       | RCT DB       | 591 (79%)                         | 35 (23–51)          | GCS ≤ 8              | Loading dose 0.7 mg/kg per 1 h intravenously, followed by 0.50 mg/kg per 1 h for 119 h | GOS 6 months |
| Wright31            | TBI       | RCT DB       | 422 (73%)                         | 36 (17–93)          | 4 < GCS < 12         | Loading dose within 4 h of injury 14 mL/h for 1 h, then 10 mL/h for 71 h, dose then tapered by 2.5 mL/h every 8 h for total treatment of 96 h | GOS-E 6 months |
| Sinha37             | TBI       | RCT (blinding nr) | 26 (76%) | 33.7 (10.9) | GCS ≤ 8 | Within 8 h of injury, 1.0 mg/kg via intramuscular injection, one every 12 h for 5 consecutive days | GOS 6 months |
| Soltani32           | DAI       | RCT SB       | 24 (100%)                         | 27.9 (1.4)          | 3 < GCS < 12         | 1 mg/kg every 12 h for 5 days | GOS-E 6 months |
| **Erythropoietin**  |           |              |                                   |                     |                      |              |                                  |
| Robertson322        | TBI       | RCT with factorial design | EpO1 = 35 (90%) EpO2 = 57 (86%) | 89 (86%) | GCS > 3 | EpO1: one dose of 500 IU/kg within 6 h of injury, then two additional doses every 24 h (changed in 2009 because of safety) EpO2: one dose of 500 IU/kg, within 6 h of injury | GOS 6 months |
| Nichol33            | TBI       | RCT DB       | 308 (84%)                         | 30.5 (22.4–47.5)    | 3 < GCS < 12         | Within 24 h of injury, 40,000 IU subcutaneously, then weekly for max of 3 doses | GOS-E 6 months |
| Li34                | TBI       | RCT DB       | 79 (65%)                          | 43.3 (10.1)         | GCS ≤ 8              | Subcutaneous injection of Epo (100 units/kg) in 5 doses (day 1, 3, 6, 9, 12) | GOS 3 months |
| Bai and Gao35       | TBI       | RCT DB       | 60 (68%)                          | 44.5 (11.4)         | GCS < 8              | Subcutaneous injection of RHE (6000 IU) within 2 h of admission, same dosage on day 3, 5, 10 and 15 | GOS 10 weeks |
| **Cyclosporine**    |           |              |                                   |                     |                      |              |                                  |
| Hatton36            | TBI       | RCT DB       | 32 (75%)                          | 8 (100%) | 4 < GSC < 8 | 4 cohorts, different dosing (3 cohorts with 0.625–2.5 mg/kg/dose every 12 h for 72 h (6 doses each)) 1 cohort with 2.5 mg/kg loading dose, then 5 mg/kg/day continuous infusion for 72 h | GOS 6 months |
| Mazzeo15            | TBI       | RCT Double-blind | 37 (82% males in total sample) | 34 (16) | 3 < GSC < 8 | Within 12 h of injury 5 mg/kg of CsA, over 24 h | GOS 6 months |
| Aminmansour26       | DAI       | RCT DB       | 50 (90%)                          | 29.9 (8.7)          | GCS ≤ 10             | Within 8 h of injury 5 mg/kg, via 250 ml dextrose water for 24 h | GOS-E 6 months |
Table 1. Overview of the included studies. SD standard deviation, IQR inter quartile range, TBI traumatic brain injury, DAI diffuse axonal injury, RCT randomized controlled trial, DB double-blind, SB single-blind, GCS Glasgow Coma Scale, GOS Glasgow Outcome Scale, GOS-E Extended Glasgow Outcome Scale, IU international unit, RHE recombinent human erythropoietin, n.r. not retrieved from the article. *Not reported for final sample, numbers are retrieved from demographics Table describing the total number of enrolled patients.

| Group by drug | Study name | Risk ratio | Lower limit | Upper limit | p-Value |
|---------------|------------|------------|-------------|-------------|---------|
| CsA           | Hatton et al. 2008 | 5.00 | 0.33 | 76.81 | 0.248 |
| CsA           | Mazzeo et al. 2009 | 0.67 | 0.37 | 1.21 | 0.181 |
| CsA           | Aminmansour et al. 2018 | 0.75 | 0.50 | 1.13 | 0.167 |
| CsA           | Aminmansour et al. 2018 | 0.75 | 0.49 | 1.15 | 0.189 |
| Epo           | Robertson et al. 2014 | 0.97 | 0.66 | 1.41 | 0.863 |
| Epo           | Nichol et al. 2015 | 1.01 | 0.87 | 1.17 | 0.897 |
| Epo           | Li et al. 2016 | 1.89 | 1.36 | 2.63 | 0.000 |
| Epo           | Bai & Gao 2018 | 1.22 | 0.95 | 1.58 | 0.126 |
| Epo           | 1.20 | 0.96 | 1.51 | 0.110 |
| Progesterone  | Wright et al. 2007 | 1.65 | 0.63 | 4.29 | 0.305 |
| Progesterone  | Xiao et al. 2008 | 1.37 | 1.00 | 1.87 | 0.053 |
| Progesterone  | Aminmansour et al. 2012 | 1.80 | 0.73 | 4.43 | 0.201 |
| Progesterone  | Shakeri et al. 2013 | 1.73 | 0.96 | 3.12 | 0.070 |
| Progesterone  | Skolnick et al. 2014 | 1.00 | 0.89 | 1.12 | 0.976 |
| Progesterone  | Wright et al. 2014 | 0.91 | 0.80 | 1.04 | 0.178 |
| Progesterone  | Soltani et al. 2017 | 1.34 | 1.02 | 1.77 | 0.037 |
| Progesterone  | Sinha et al. 2017 | 1.70 | 1.01 | 2.88 | 0.048 |
| Progesterone  | 1.22 | 1.01 | 1.46 | 0.040 |
| Overall       | 1.15 | 1.01 | 1.32 | 0.041 |

Figure 2. Meta-analysis including 15 studies evaluating the effect of drugs with anti-inflammatory properties on a favorable outcome in TBI patients.

Figure 3. Funnel plot showing publication bias in the overall analyses (15 studies), including imputed studies (black circles).
For erythropoietin (four studies), the RR was similar to progesterone yet did not reach significance (RR 1.20; 95% CI 0.96–1.52; p = 0.110; Fig. 2). There was a significant level of heterogeneity across the erythropoietin studies (Q(3) = 12.81, p = 0.005; I2 = 76.79%). Cyclosporine (three studies) did not show a significant effect with low heterogeneity (RR 0.75; 95% CI 0.49–1.17, p = 0.189; Q(2) = 2.00. p = 0.369; I2 = 0%; Fig. 2). Due to the low number of studies included for both erythropoietin and cyclosporine, no moderator analyses could be performed. 

Discussion

This study investigated if agents with anti-inflammatory properties can help to ameliorate functional and neurological recovery in patients suffering from consequences of traumatic brain injury (TBI). In total, 15 studies were summarized for quantitative analysis to gain perspective on how current literature provides evidence for efficacy of anti-inflammatory drugs, including three different components: progesterone, erythropoietin and cyclosporine. The overall effect of these drugs with anti-inflammatory properties turned out to be significant yet small (RR = 1.15), with considerable heterogeneity among studies. A faster time to treatment after injury could be a factor of interest for the beneficial effects of agents with anti-inflammatory properties in TBI patients, although this did not reduce heterogeneity. When drug type was tested for efficacy in improving outcome, progesterone showed a small effect size, yet heterogeneity among studies remained high. As a small improvement is easily out-weighted by the risk of side-effects, which was not tested in this study, positive recommendation for clinical use is premature. Furthermore, publication bias was observed in the overall analysis and the studies reporting progesterone efficiency, which reflects proneness to publication of studies only reporting positive results. No effects were found for erythropoietin and cyclosporine.

This is the first quantitative analysis that provides evidence on the overall efficacy of drugs with anti-inflammatory properties in TBI. In order to be as inclusive as possible, we broadly selected agents that have shown some anti-inflammatory effects, which resulted in a total number of 15 clinical trials on three different components. The overall positive RR of 1.15 was small yet significant, but results need to be interpreted with caution due to the publication bias that was indicated as well as the high heterogeneity among the included studies. Moreover, progesterone was the most investigated component and two of those trials had an exceptionally large sample size (n > 850). While intervention duration, age, or gender distribution did not moderate the overall effect of drugs with anti-inflammatory properties on a favorable outcome in TBI, we did find that efficacy may be dependent on time of treatment. Studies administrating an agent with anti-inflammatory effects within 8 h after injury showed a significant combined RR of 1.20 as compared to placebo, while trials with a longer administration time resulted in a lower and insignificant combined RR of 1.05. However, this latter result was based on a relatively small number of four trials (subtotal n = 876 participants) and we must note that heterogeneity remained high among the faster administration trials. Although issues with the quality and clinical relevance of the preclinical animal models have been noted, animal studies have also suggested that a faster administration time can positively moderate treatment outcome. For example, the strongest anti-inflammatory effect of progesterone can be expected when dosed 1 h after the injury, or within 6 h for erythropoietin.

**Progesterone.** Progesterone has multiple anti-inflammatory actions and its effects on brain edema involves complex mechanisms and inflammatory mediators. Multiple animal studies investigating the efficacy of progesterone on improving outcome after TBI have yielded positive results. Combining eight studies in patients with TBI, our results show that progesterone treatment can elicit a small positive effect on favorable outcome, which is in line with a previous meta-analysis. We observed high heterogeneity between the included studies and the analysis stratified by administration route indicated that the effect of progesterone was mainly observed when administered intramuscularly (RR 1.41); not when patients received progesterone intravenously (RR 0.97). Notably, intramuscular administration was mainly implemented by the relatively smaller studies, while the studies with larger sample sizes investigated the intravenous route. Moreover, we found that age cova-
Erythropoietin. Animal studies have reported on the efficacy of erythropoietin against multiple early mediators of secondary brain injury, including anti-inflammatory effects in terms of reducing proinflammatory cytokines as well as increasing anti-inflammatory cytokines in brain tissue. In turn, these anti-inflammatory effects supposedly contribute to the erythropoietin-induced neuroprotective effects after TBI. Contrasting animal work, the present study (including four RCTs) did not confirm the effectiveness of erythropoietin in improving neurological recovery. The RR for erythropoietin was similar to progesterone yet did not reach significance, which could indicate a power problem. This negative finding corroborates a previous meta-analysis by Lee et al. including three RCTs, who did show that the use of EPO may prevent death following TBI. The study by Li et al. was the only positive erythropoietin study in our meta-analysis, with a large effect size of 1.89. Compared to the other three trials with null-results, Li et al. administered the first dose relatively fast, within 2 h of admission. This treatment timeframe was similar to the recent study by Bai and Gao, who sampled a slightly lower number of participants and found a positive yet lower effect size of 1.22 that did not reach significance ($p = 0.126$). Animal studies also suggest that earlier administration, preferably within 6 h, seems to elicit the most effect, although positive effects have also been shown when administered one-day post injury. Although we could not perform a moderator analysis for erythropoietin dosage within our meta-analysis, Gantner et al. ran post hoc analyses for the large EPO-TBI trial by Nichol et al. and reported that the strongest benefit was seen in patients who received two doses of erythropoietin.

Cyclosporine. In spite of existing evidence for cyclosporine anti-inflammatory action, only few clinical trials with this component have been performed to test its effect on neurological recovery. So far, its neuroprotective role has mainly been tested in animal models, which underline the importance of initiating administration of cyclosporine as soon as possible following TBI. We could only include three studies and found that the overall effect size did not favor cyclosporine treatment. Although none of the individual trials reached significance, two studies showed a RR below 1.00 while Hatton et al. was an exceptionally large positive outlier (RR 5.00), potentially because none of the patients gained a favorable outcome in the much smaller control group ($n = 8$, versus a treatment group of $n = 32$). As cyclosporine is listed as a potential treatment therapy for TBI, our negative results urge caution and highlight the need for additional studies on this component.

Limitations. The pathogenesis of TBI is complex and outcome is determined by different mechanisms and level of severity, neuroanatomical location and distribution of brain lesions. Each TBI patient has an unique pattern of cerebral damage. This heterogeneity of injury patterns make it even harder to develop effective therapies that could target multiple cellular and molecular events and will be applicable for each patient suffering from TBI. The diversity and complexity could be the reason for several failed clinical trials despite successful procedures in experimental settings. Therefore, only few trials could be included per component investigated, which limits the impact of our findings. Regarding the chosen outcome measure, the Glasgow Outcome Scale (GOS) and Extended Glasgow Outcome Scale (GOS-E), are confirmed to be reliable and most accepted instrument available. In addition, researchers have found a significant correlation between performance on the neuropsychological measures and the GOS-E scores. However, was recommended by the TBI Clinical Trials Network Outcome Measure Subcommittee, a single, global measure is less suitable in evaluating multiple domains of recovery from TBI. Within our meta-analysis, only two out of 15 studies had included additional neuropsychological testing. In future studies, more sensitive outcome measures should be implemented that can differentiate degrees of functional outcome.

Modulation of the inflammatory pathway may also be an important mechanism underlying the effects of other agents that have previously shown therapeutic benefit in TBI treatment, as described in an extensive review by Bergold. For example statin use, with a double-blind RCT in 36 patients with moderate and severe TBI showing that rosuvastatin reduces disability scores together with TNF-α, no effect was found on IL-1β, IL-6, and IL-10. Moreover, modification of the neuroinflammatory response has also been found for recombinant human IL-1ra (rhIL-1ra, anakinra), in a phase II, open label, randomized-control study including 20 patients with severe TBI. More knowledge on the anti-inflammatory mechanisms behind such pharmacological components can help to improve (pre)clinical testing of agents in the search for effective TBI treatment.

Conclusion

Based on the available literature, it is too early to draw any conclusions on the efficacy of drugs with anti-inflammatory properties in the treatment of TBI patients. Progesterone showed some promising results in improving the outcome of TBI patients yet verification is needed. To strengthen the body of research on TBI treatment, future well-designed trials are needed to evaluate the factors that could potentially moderate treatment effects, including the initial time of treatment after injury, administration route but also patient characteristics such as age of the patient suffering from TBI.
References

1. Finnie, J. Neuroinflammation: Beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology 21, 309–320 (2013).

2. Narayan, R. K. et al. Clinical trials in head injury. J. Neurotrauma 19, 503–557 (2002).

3. Benedictus, M. R., Spikman, J. M. & van der Naalt, J. Cognitive and behavioral impairment in traumatic brain injury related to outcome and return to work. Arch. Phys. Med. Rehabil. 91, 1436–1441 (2010).

4. Cifu, D. & Caruso, D. Traumatic Brain Injury: Rehabilitation Medicine Quick Reference 1st edn. (New York, Demos Medical Publishing, 2010).

5. Cederberg, D. & Siesjö, P. What has inflammation to do with traumatic brain injury?. Childs Nerv. Syst. 26, 221–226 (2010).

6. Russo, M. & McGavern, D. Inflammatory neuroprotection following traumatic brain injury. Science (NY) 353, 783–785 (2016).

7. Schmidt, O. I., Heyde, C. E., Ertel, W. & Stahel, P. F. Closed head injury—An inflammatory disease?. Brain Res. Rev. 48, 388–399 (2005).

8. Morganti-Kossmann, M. F., Rancan, M., Stahel, P. & Kossmann, T. Inflammatory response in acute traumatic brain injury: A double-edged sword. Curr. Opin. Crit. Care 8, 101–105 (2002).

9. Lenzlinger, P., Morganti-Kossmann, M., Laufer, H. & McIntosh, T. The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol. 24, 169–181 (2001).

10. Zhou, Z. W. et al. Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury. Brain Res. 1531, 367–380 (2016).

11. Meng, Y. et al. Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. J. Neurosurg. 115, 550–560 (2011).

12. Yatsiv, I. et al. Erythropoietin regulates immune/inflammatory reaction and improves neurological function outcomes in traumatic brain injury. Brain Behav. 7, e00827 (2017).

13. Sinha, S. et al. A randomized placebo-controlled trial of progesterone with or without hypothermia in patients with acute severe traumatic brain injury. Brain Inj. 30, 687 (2016).

14. Shukla, D., Devi, B. I. & Agrawal, A. Outcome measures for traumatic brain injury. BMJ 349, 1–7 (2007).

15. Wright, D. W. et al. Erythropoietin in traumatic brain injury (EPO-TBI): A double-blind randomised controlled trial. Lancet 368, 2467–2476 (2009).

16. Nichol, A. et al. Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double-blind controlled clinical trial. JAMA 312, 36–47 (2014).

17. Schizophr. Bull. 40, 181–191 (2014).

18. Chen, G., Shi, J. X., Qi, M., Wang, H. X. & Hang, C. H. Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats. J. Surg. Res. 147, 92–98 (2008).

19. Lei, B., Mace, B., Dawson, H. N., Warner, D. S., Laskowitz, D. T. & James, M. L. Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. PLoS one 9(7), e103869 (2014).

20. Shukla, D., Devi, B. I. & Agrawal, A. Outcome measures for traumatic brain injury. Clin. Neurol. Neurosurg. 113, 435–441 (2011).

21. Lin, C. et al. Efficacy of progesterone for moderate to severe traumatic brain injury: A meta-analysis of randomized clinical trials. Sci. Rep. 5, 13442 (2015).

22. Wright, D. W. et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49, 391–402 (2007).

23. Robertson, C. S. S. et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: A randomized clinical trial. JAMA 312, 36–47 (2014).

24. Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. Introduction to Meta-Analysis (Wiley, Chichester, 2009).

25. Alderson, P. & Roberts, I. Erythropoietin regulates immune/inflammatory reaction and improves neurological function outcomes in traumatic brain injury. Brain Behav. 7, e00827 (2017).

26. CRASH Trial Collaborators. Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant traumatic brain injury in the CRASH trial is based on problematic meta-analysis. J. Neurotrauma 35, 1915–1918 (2017).

27. Cutler, S. M., Pettus, E. H., Hoffman, S. W. & Stein, D. G. Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury. Exp. Neurol. 195, 423–429 (2005).

28. Tang, H. et al. Progesterone and vitamin D: Improvement after traumatic brain injury in middle-aged rats. Horm. Behav. 64, 527–538 (2013).

29. Cherian, L., Goodman, J. & Robertson, C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J. Pharmacol. Exp. Ther. 322, 789–794 (2007).

30. Si, D. et al. Progesterone regulates blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats. Exp. Ther. Med. 8, 1010–1014 (2014).
43. Cutler, S. et al. Progesterone improves acute recovery after traumatic brain injury in the aged rat. J. Neurotrauma 24, 1475–1486 (2007).
44. Hua, F. et al. Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: Effect of exogenous progesterone. J. Neuroinflamm. 8, 42 (2011).
45. Pan, Z. Y., Zhao, Y. H., Huang, W. H., Xiao, Z. Z. & Li, Z. Q. Effect of progesterone administration on the prognosis of patients with severe traumatic brain injury: A meta-analysis of randomized clinical trials. Drug Des. Devel. Ther. 13, 265–273 (2019).
46. Stein, D. G. & Cekic, M. M. Progesterone and vitamin D hormone as a biologic treatment of traumatic brain injury in the aged. PM R 3, S100–S110 (2011).
47. Kawakami, M., Iwasaki, S., Sato, K. & Takahashi, M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem. Biophys. Res. Commun. 279, 293–297 (2000).
48. Lee, J. et al. Efficacy and safety of erythropoietin in patients with traumatic brain injury: A systematic review and meta-analysis. Am. J Emerg. Med. 37, 1101–1107 (2019).
49. Gantner, D. C. et al. Erythropoietin to reduce mortality in traumatic brain injury: A post-hoc dose-effect analysis. Ann. Surg. 267, 585–589 (2018).
50. Pahl, A. et al. Anti-inflammatory effects of a cyclosponge receptor-binding compound, D-43787. J. Pharmacol. Exp. Ther. 301, 738–746 (2002).
51. Yadav, S., Pawar, G., Kulkarni, P., Ferris, C. & Amiji, M. CNS delivery and anti-inflammatory effects of intranasally administered acyclovir-A in cationic nanofluidations. J. Pharmacol. Exp. Ther. 370, 843–854 (2019).
52. Sullivan, P., Sebastian, A. & Hall, E. Therapeutic window analysis of the neuroprotectoric effects of cyclosponge A after traumatic brain injury. J. Neurotrauma 28, 311–318 (2011).
53. Joseph, B., Khan, M. & Rhee, P. Non-invasive diagnosis and treatment strategies for traumatic brain injury: An update. J. Neurosci. Res. 96, 589–600 (2018).
54. Goldstein, F. et al. Very early administration of progesterone does not improve neuropsychological outcomes in subjects with moderate to severe traumatic brain injury. J. Neurotrauma 34, 115–120 (2017).
55. Wilson, J., Pettigrew, L. & Teasdale, G. Emotional and cognitive consequences of head injury in relation to the Glasgow outcome scale. J. Neurol. Neurosurg. Psychiatry 69, 204–209 (2000).
56. Gruenbaum, S. E., Zlotnik, A., Gruenbaum, B. F., Hersey, D. & Bilotta, F. Pharmacologic neuroprotection for functional outcomes after traumatic brain injury: A systematic review of the clinical literature. CNS Drugs 30, 791–806. https://doi.org/10.1007/s40263-016-0355-2 (2016).
57. Sanchez-Aguilar, M. et al. Effect of rosuvastatin on cytokines after traumatic head injury. J. Neurosurg 118(3), 669–675 (2013).
58. Helmy, A. et al. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: A phase II randomized control trial. J. Cerebr. Blood F. Met. 34(5), 845–851 (2014).

Acknowledgements
This work was supported by the Dutch Brain Foundation (Hersenstichting, number PZ 2017.01.2, 2017), received by Prof. Dr. Sommer and Dr. Begemann. We thank the authors that replied to e-mail requests for additional data or further clarification of their results.

Author contributions
M.B., M.L. and I.S. wrote the main manuscript text, M.L. prepared Fig. 1 and M.B. prepared Figs. 2, 3 and 4. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-73227-5.

Correspondence and requests for materials should be addressed to M.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020